Literature DB >> 12730742

Gene expression studies of osteoporosis: implications for microarray research.

V Dvornyk1, R R Recker, H-W Deng.   

Abstract

Osteoporosis is one of the most common bone-related disorders in the elderly. It is a complex disease, and largely determined genetically. Traditional gene expression studies have shown that osteoporosis has complex regulating mechanisms which are controlled by multiple inherent factors, such as hormones, cytokines, various receptors, etc. The complex nature of osteoporosis, and the large number of genes involved in its onset and development, suggest the use of the state of the art microarray technique as a powerful tool to unravel mechanisms underlying etiology of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730742     DOI: 10.1007/s00198-002-1373-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  126 in total

1.  The expression and regulation of class II antigens in normal and inflammatory bowel disease peripheral blood monocytes and intestinal epithelium.

Authors:  P Salomon; A Pizzimenti; A Panja; A Reisman; L Mayer
Journal:  Autoimmunity       Date:  1991       Impact factor: 2.815

Review 2.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

3.  Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis.

Authors:  David G Stokes; Gang Liu; Ibsen B Coimbra; Sonsoles Piera-Velazquez; Robert M Crowl; Sergio A Jiménez
Journal:  Arthritis Rheum       Date:  2002-02

4.  Epidemiology of vertebral fractures in women.

Authors:  L J Melton; S H Kan; M A Frye; H W Wahner; W M O'Fallon; B L Riggs
Journal:  Am J Epidemiol       Date:  1989-05       Impact factor: 4.897

5.  Metacarpal morphometry in monozygotic dizygotic elderly twins.

Authors:  M Møller; A Horsman; B Harvald; M Hauge; K Henningsen; B E Nordin
Journal:  Calcif Tissue Res       Date:  1978-05-26

6.  Bone remodeling in response to in vivo fatigue microdamage.

Authors:  D B Burr; R B Martin; M B Schaffler; E L Radin
Journal:  J Biomech       Date:  1985       Impact factor: 2.712

7.  Estrogen modulates osteoblast proliferation and function regulated by parathyroid hormone in osteoblastic SaOS-2 cells: role of insulin-like growth factor (IGF)-I and IGF-binding protein-5.

Authors:  M Nasu; T Sugimoto; H Kaji; K Chihara
Journal:  J Endocrinol       Date:  2000-11       Impact factor: 4.286

8.  Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo.

Authors:  Daichi Chikazu; Xiaodong Li; Hiroshi Kawaguchi; Yoko Sakuma; Olga S Voznesensky; Douglas J Adams; Manshan Xu; Kazuto Hoshio; Vedran Katavic; Harvey R Herschman; Lawrence G Raisz; Carol C Pilbeam
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

9.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.

Authors:  L C Hofbauer; C R Dunstan; T C Spelsberg; B L Riggs; S Khosla
Journal:  Biochem Biophys Res Commun       Date:  1998-09-29       Impact factor: 3.575

10.  Expression of leukemia inhibitory factor (LIF)/interleukin-6 family cytokines and receptors during in vitro osteogenesis: differential regulation by dexamethasone and LIF.

Authors:  F Liu; J E Aubin; L Malaval
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

View more
  1 in total

1.  Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis.

Authors:  Conor J Hurson; Joseph S Butler; Dominic T Keating; David W Murray; Denise M Sadlier; John M O'Byrne; Peter P Doran
Journal:  BMC Musculoskelet Disord       Date:  2007-02-12       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.